Cargando…

Proteomics of CKD progression in the chronic renal insufficiency cohort

Progression of chronic kidney disease (CKD) portends myriad complications, including kidney failure. In this study, we analyze associations of 4638 plasma proteins among 3235 participants of the Chronic Renal Insufficiency Cohort Study with the primary outcome of 50% decline in estimated glomerular...

Descripción completa

Detalles Bibliográficos
Autores principales: Dubin, Ruth F., Deo, Rajat, Ren, Yue, Wang, Jianqiao, Zheng, Zihe, Shou, Haochang, Go, Alan S., Parsa, Afshin, Lash, James P., Rahman, Mahboob, Hsu, Chi-yuan, Weir, Matthew R., Chen, Jing, Anderson, Amanda, Grams, Morgan E., Surapaneni, Aditya, Coresh, Josef, Li, Hongzhe, Kimmel, Paul L., Vasan, Ramachandran S., Feldman, Harold, Segal, Mark R., Ganz, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564759/
https://www.ncbi.nlm.nih.gov/pubmed/37816758
http://dx.doi.org/10.1038/s41467-023-41642-7
Descripción
Sumario:Progression of chronic kidney disease (CKD) portends myriad complications, including kidney failure. In this study, we analyze associations of 4638 plasma proteins among 3235 participants of the Chronic Renal Insufficiency Cohort Study with the primary outcome of 50% decline in estimated glomerular filtration rate or kidney failure over 10 years. We validate key findings in the Atherosclerosis Risk in the Communities study. We identify 100 circulating proteins that are associated with the primary outcome after multivariable adjustment, using a Bonferroni statistical threshold of significance. Individual protein associations and biological pathway analyses highlight the roles of bone morphogenetic proteins, ephrin signaling, and prothrombin activation. A 65-protein risk model for the primary outcome has excellent discrimination (C-statistic[95%CI] 0.862 [0.835, 0.889]), and 14/65 proteins are druggable targets. Potentially causal associations for five proteins, to our knowledge not previously reported, are supported by Mendelian randomization: EGFL9, LRP-11, MXRA7, IL-1 sRII and ILT-2. Modifiable protein risk markers can guide therapeutic drug development aimed at slowing CKD progression.